Author: [email protected]

Release – Xcel Brands Announces Licensing Agreement with KBL Group for OFF/DUTY by Coco Rocha

Posted on by [email protected]
Primary Logo

Research News and Market Data on XELB

PDF Version

NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB), a leading media and consumer products company specializing in influencer-led brands through social commerce and livestream shopping, today announced a licensing agreement with KBL Group for OFF/DUTY by Coco Rocha, the elevated fashion and accessories brand created in collaboration with internationally recognized supermodel, entrepreneur, educator, and fashion icon Coco Rocha.

Under the agreement, KBL Group will serve as the production partner for OFF/DUTY by Coco Rocha’s ready to wear collections, leveraging their expertise in sourcing, product development, manufacturing, and supply chain management to bring the brand’s vision to life. The partnership will support the continued growth of OFF/DUTY by Coco Rocha as the brand expands its fashion offerings across multiple retail distribution channels.

OFF/DUTY by Coco Rocha was created to reflect the realities of modern life, offering elevated wardrobe essentials designed for women constantly on the move. Inspired by the pieces Coco has relied on throughout her two-decade career of fashion weeks, international travel, business meetings, and family life. The brand delivers stylish, versatile, and functional pieces that seamlessly transition from day to night.

“KBL Group brings exceptional expertise in product development and manufacturing, making them an ideal partner for OFF/DUTY by Coco Rocha,” said Robert W. D’Loren, Chairman and Chief Executive Officer of Xcel Brands. “As we continue to build the brand, having a best-in-class partner capable of executing Coco’s vision with the highest standards of quality and craftsmanship is critical. We are excited to work together to create collections that resonate with today’s modern consumer.”

David Guisinger, Chief Executive Officer of KBL Group, added, “We are proud to partner with XCEL Brands and OFF/DUTY by Coco Rocha to bring a modern approach to dressing that is both aspirational and accessible. Coco’s authentic point of view and deep understanding of how women dress today have created a powerful foundation for the brand. By combining XCEL’s innovative approach to brand building with KBL’s expertise in product development, sourcing and execution, we are creating a meaningful lifestyle brand that reflects today’s consumer, confident, versatile and effortlessly sophisticated, while developing growth opportunities across multiple channels of distribution.”

About Xcel Brands

Xcel Brands, Inc. (NASDAQ: XELB) is a media and consumer products company engaged in the design, licensing, marketing, live streaming, and social commerce sales of branded apparel, footwear, accessories, fine jewelry, home goods, pet products and other consumer products, and the acquisition of dynamic consumer lifestyle brands. Xcel was founded in 2011 with a vision to reimagine shopping, entertainment, and social media as social commerce. Xcel is an industry leader in developing influencer led brands and owns the Halston and C. Wonder brands, as well as the co-branded influencer led brands Tower Hill by Christie Brinkley, Trust. Respect. Love by Cesar Millan, GemmaMade by Gemma Stafford and OFF/DUTY by Coco Rocha brand and holds a long-term license agreement in Mesa Mia by Jenny Martinez. Xcel also owns and manages the Longaberger by Shannon Doherty brand through its controlling interest in Longaberger Licensing, LLC. Xcel is pioneering a modern consumer products sales strategy which includes the promotion and sale of products under its brands through interactive television, digital live-stream shopping, social commerce, brick-and-mortar retailers, and e-commerce channels to be everywhere its customers’ shop. The company’s previously owned and current brands have generated more than $5 billion in retail sales via livestreaming in interactive television and digital channels alone and has over 20,000 hours of content production time in live-stream and social commerce. The brand portfolio reaches more than 46 million social media followers with broadcast reaching 200 million households. Headquartered in New York City, Xcel Brands is led by an executive team with significant live streaming, production, merchandising, design, marketing, retailing, and licensing experience, and a proven track record of success in elevating branded consumer products companies. For more information, visit www.xcelbrands.com.

For further information please contact:

Xcel Brands
[email protected]

About KBL Group

KBL Group is a globally-focused fashion brand development and sourcing partner that supports retailers and designers at every stage of the product lifecycle.  With a legacy that traces back to 1985, KBL has evolved into a strategic extension of its clients’ teams, blending market insight, creative design and international supply chain execution into comprehensive brand solutions.  Today, KBL Group operates with an integrated presence in New York and Hong Kong, aligning it’s global expertise to help fashion and lifestyle brands navigate a competitive, rapidly-changing marketplace.

For further information please contact:

KBL Group
[email protected]

About Coco Rocha

Coco Rocha is an internationally recognized supermodel, entrepreneur, educator, author, mentor, and advocate. Often referred to as the “Queen of Pose,” she has spent more than two decades at the forefront of the fashion industry, appearing on hundreds of magazine covers, walking for the world’s leading luxury brands, and starring in major global advertising campaigns.

Beyond modeling, Rocha has built a successful business career spanning fashion, education, television, and digital media. She is the founder of Coco Rocha Model Camp, where she has mentored thousands of aspiring and professional models from around the world, and currently serves as mentor and host of Project Runway Canada. Known for combining creativity, entrepreneurship, and education, Rocha continues to shape the future of fashion while inspiring audiences through her work as a businesswoman, mentor, and mother.

Primary Logo

Release – NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: “A Quest to Outrun ALS”

Posted on by [email protected]

Research News and Market Data on NRSN

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC’s path forward

CAMBRIDGE, Mass., July 6, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced its participation in a key opinion leader (KOL) webinar hosted by Roth Capital Partners titled “A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS).” The webinar will bring together leading experts to discuss the current treatment landscape for ALS, persistent unmet medical needs, and emerging therapeutic approaches with the potential to change the course of the disease.

The live webinar will take place on Wednesday, July 8, 2026, at 11:00 a.m. Eastern Time and will be hosted by Boobalan Pachaiyappan, Ph.D., Managing Director and Senior Research Analyst at Roth Capital Partners, who covers the biotechnology sector. The discussion will feature Professor Jeremy Shefner, M.D., Ph.D., Chair of Neurology at Barrow Neurological Institute and Co-Founder of the Northeast ALS Consortium (NEALS), together with Alon Ben-Noon, Chief Executive Officer of NeuroSense.

To join the conversation, register in advance here.

The webinar will explore the most pressing questions in ALS drug development today – from the persistent unmet needs that continue to challenge patients and clinicians, to the clinical trial endpoints that may better capture disease progression. The discussion will also examine how NeuroSense’s PrimeC is positioned – mechanistically and clinically – relative to the current standard of care, what the pivotal Phase 3 PARAGON study will aim to demonstrate on the path toward potential FDA accelerated approval, and PrimeC’s longer-term commercial opportunity within an evolving ALS treatment landscape.

About NeuroSense

NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The Company’s lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.

NeuroSense has generated compelling clinical data from its Phase 2b PARADIGM study in ALS, demonstrating meaningful slowing of disease progression. The Company also reported significant biological activity across multiple biomarkers associated with ALS, including microRNAs, supporting PrimeC’s multi-target mechanism of action. Notably, long-term follow-up data indicated a meaningful survival benefit, representing a potentially important advancement in the treatment of ALS.

NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pivotal Phase 3 clinical trial (PARAGON) in ALS, which is expected to enroll approximately 300 participants, primarily in the United States.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation to potentially inhibit the progression of ALS and AD.

About ALS

Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements, including statements regarding the planned event, development, regulatory progress and potential commercialization of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding the benefits of outcomes and the timing of current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

SOURCE NeuroSense

For further information: Email: [email protected] | Tel: +972 (0)9 799 6183

Release – Kratos Expands Oklahoma City Manufacturing Facility to Accelerate Production of Valkyrie, Firejet and Other Jet Drone Systems

Posted on by [email protected]
Primary Logo

Research News and Market Data on KTOS

July 6, 2026

PDF Version

106,000 Square Foot Facility Expansion Reflects Increased Demand for Kratos Jet Drones and Kratos’ Continued Investment in Strengthening the United States Defense Industrial Base Through Scalable, Efficient Manufacturing Capacity Capable of Producing Affordable, Mission-Ready Systems at Quantity and at Speed

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in the defense, national security and global markets, today announced a major expansion of its Oklahoma City manufacturing campus with the addition of over 100,000 square feet of manufacturing and production space. The expansion supports increasing customer demand for the company’s family of high-performance, affordable jet-powered drone systems, including the Valkyrie collaborative combat aircraft, the Firejet/Mighty Hornet IV and others.

The facility expansion represents Kratos’ continued investment in strengthening the United States defense industrial base through scalable, efficient manufacturing capacity capable of producing affordable, mission-ready systems at quantity and at speed. Today, Kratos produces approximately 165 high-performance jet drones annually, and this expansion will enable the company to further increase production to meet growing demand from the U.S. Department of War and allied customers.

“The future fight demands the ability to rapidly produce affordable, high-performance systems at scale,” said Steve Fendley, President of Kratos Unmanned Systems Division. “This expansion in Oklahoma City reflects our long-term commitment to investing ahead of customer demand and building the industrial capacity needed to support the Department of War’s modernization priorities. As autonomous systems become increasingly central to the future force, manufacturing readiness and producing at scale will be just as important as technology readiness, maybe more.”

The expanded facility will provide additional manufacturing, assembly, integration and test capacity for multiple Kratos tactical jet aircraft programs.

Production will support Valkyrie, the affordable, runway-flexible collaborative combat aircraft selected by the U.S. Marine Corps as the foundation of its Collaborative Combat Aircraft (CCA) program of record. Designed to operate solo, in swarms, or alongside crewed aircraft while providing additional mass, reach and mission capability, Valkyrie represents a new generation of affordable autonomous airpower. The expanded facility will also manufacture the Mighty Hornet IV, which is expected to serve as a key tactical capability supporting Taiwan’s defense requirements, reflecting growing international demand for affordable, high-performance unmanned systems.

The expanded facility will also support increased production capacity for Kratos’ family of high-performance aerial target systems, including the Firejet. Kratos’ Firejet system supports realistic operational test, evaluation and weapons training across the U.S. military and allied nations, with demand for advanced target capabilities continuing to grow, including for the test and training of missile, radar, air defense, C-UAS and directed energy weapon systems, and their crews.

Kratos has consistently invested in manufacturing infrastructure, production technologies, and workforce development to ensure the company can deliver affordable systems at the pace and scale required by evolving national security needs. The Oklahoma City expansion is the latest in a series of investments focused on expanding domestic production capacity and strengthening the resilience of the U.S. defense industrial base.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com and follow Kratos on LinkedIn and X.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 28, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
[email protected]

Kratos Investor Information:
877-934-4687
[email protected]

Primary Logo

Release – CoreCivic Sells Two Detention Facilities\

Posted on by [email protected]
CoreCivic

Research News and Market Data on CXW

July 6, 2026

PDF Version

BRENTWOOD, Tenn., July 06, 2026 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (CoreCivic or the Company) announced today that on July 2nd, 2026, it completed the sale of its 2,560-bed California City Detention Facility in California City, California (the California City Facility) and its 1,994-bed Otay Mesa Detention Center in San Diego, California (the Otay Mesa Facility) to the United States of America and its assigns, by and through the Department of Homeland Security for an aggregate gross sales price of $1.5 billion, including $732.6 million for the California City Facility and $739.2 million for the Otay Mesa Facility. These two purpose-built facilities were specifically designed to care for individuals in a secure environment. After federal and state income taxes of approximately $0.4 billion and transaction expenses, the Company anticipates its net proceeds from the asset sales to be approximately $1.1 billion.

The Company expects to use a portion of the net proceeds from the asset sales to

  • Repay all or a portion of the outstanding indebtedness under the Company’s Bank Credit Facility, which currently has an outstanding balance of $270.0 million on the Revolving Credit Facility, $107.8 million on the Initial Term Loan, and $100.0 million on the Incremental Term Loan, and
  • Repay the remaining outstanding balance of $238.5 million of the Company’s 4.75% senior notes, which are scheduled to mature in October 2027 (the 4.75% Notes).

The Company expects to use the remaining net proceeds for general corporate purposes, which may include additional debt repayments and share repurchases of the Company’s common stock. The credit agreement governing the Company’s Bank Credit Facility (the Credit Agreement) and the indenture (the 2029 Notes Indenture) governing the Company’s outstanding 8.25% senior notes due 2029 (the 8.25% Notes) limit our ability to make certain restricted payments, including share repurchases. However, the Company is permitted to make unlimited restricted payments (i) under the Credit Agreement, to the extent the Company’s consolidated secured leverage ratio (as defined therein) calculated on a pro forma basis after giving effect to such restricted payment would be equal to or less than 1.50 to 1.00 and no default exists thereunder, and (ii) under the 2029 Notes Indenture, to the extent the Company’s consolidated total leverage ratio (as defined therein) calculated on a pro forma basis after giving effect to such restricted payment would be equal to or less than 2.00 to 1.00. 

The Company also expects to maintain balance sheet flexibility to pursue growth opportunities. These opportunities include, but are not limited to, potential acquisitions within the Company’s lines of business and those that provide complementary services provided such opportunities enhance the Company’s business, diversify the Company’s cash flows, and/or increase the services the Company offers to its customers, similar to the acquisition of Clinical Solutions Pharmacy completed on April 1, 2026.

The Company currently expects to continue to manage the California City Facility and the Otay Mesa Facility under the existing management contracts with Immigration & Customs Enforcement (ICE) related to each facility, although the terms of the management contracts may be modified to reflect the change in ownership. However, the Company can provide no assurance that it will continue to manage these facilities in the future, or that the terms of the existing management agreements will remain the same. As has always been the case, ICE has the ability to terminate the management contracts for non-appropriation of funds or for convenience. The management contract for the California City Facility expires in August 2027, and the management contract for the Otay Mesa Facility expires in December 2029 and contains a five-year extension option.

In addition to these asset sales, the Company has been in discussions with ICE about the potential acquisition of additional detention facilities from the Company. These discussions are in various stages, and the Company can provide no assurance that any additional sales will occur.

Patrick Swindle, CoreCivic’s President and Chief Executive Officer, commented, “We are pleased with the sales of these two mission-critical facilities for the Company’s government partner, which demonstrates the value of the Company’s underlying real estate portfolio, while reflecting our role as a long-term, flexible solutions provider to government. The sale of these facilities at what we believe is a fair valuation provides the Company with significant balance sheet flexibility and positions us well to grow the Company’s businesses and return value to its shareholders, while remaining a dependable partner for government.”

About CoreCivic

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. CoreCivic provides a broad range of solutions to government partners that help build safer, healthier, and more productive communities one person at a time through residential corrections, detention, and reentry management, adjacent service offerings that include pharmaceutical, transportation, and alternatives to incarceration, and government real estate solutions. CoreCivic is the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and one of the largest operators of such facilities in the United States. CoreCivic has been a flexible and dependable partner for government for more than 40 years. CoreCivic’s employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Forward-Looking Statements

This press release contains statements as to our beliefs and expectations of the outcome of future events that are “forward-looking” statements as defined within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. These include, but are not limited to, the risks and uncertainties associated with: (i) changes in government policy, legislation and regulations that affect utilization of the private sector for corrections, detention, and residential reentry services, in general, or our business, in particular, including, but not limited to, the continued utilization of our correctional and detention facilities by the federal government as a consequence of presidential executive orders, changes in how the federal government, including ICE, elects to use our detention capacity or otherwise procures alternative detention capacity, and the impact of any changes to immigration reform and sentencing laws (we do not, under longstanding policy, lobby for or against policies or legislation that would determine the basis for, or duration of, an individual’s incarceration or detention); (ii) our ability to obtain and maintain correctional, detention, and residential reentry facility management contracts because of reasons including, but not limited to, sufficient governmental appropriations, contract compliance, negative publicity and effects of inmate disturbances; (iii) changes in the privatization of the corrections and detention industry, the acceptance of our services, the timing of the opening of new facilities and the commencement of new management contracts (including the extent and pace at which new contracts are utilized), as well as our ability to utilize available beds; (iv) our ability to successfully activate idle facilities in a timely manner in order to meet the growth in demand for our facilities and services from the federal government that has occurred as a result of changes in policies and actions of the current presidential administration, and to realize projected returns resulting therefrom; (v) general economic and market conditions, including, but not limited to, the impact governmental budgets can have on our contract renewals and renegotiations, per diem rates, and occupancy; (vi) fluctuations in our operating results because of, among other things, changes in occupancy levels; competition; contract renegotiations or terminations; inflation and other increases in costs of operations, including a rise in labor costs; fluctuations in interest rates and risks of operations; (vii) government budget uncertainty, the impact of debt ceilings and government shutdowns, including partial shutdowns, and changing budget priorities; (viii) our ability to successfully identify and consummate future development and acquisition opportunities, integrate their operations, and realize projected returns resulting therefrom; (ix) the availability of debt and equity financing on terms that are favorable to us, or at all; and (x) the potential for additional sales and intended use of proceeds from the asset sales described in this press release. Other factors that could cause operating and financial results to differ are described in the filings we make from time to time with the Securities and Exchange Commission.

We take no responsibility for updating the information contained in this press release following the date hereof to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events or for any changes or modifications made to this press release or the information contained herein by any third-parties, including, but not limited to, any wire or internet services, except as may be required by law.

This press release is neither an offer to sell nor a solicitation of an offer to buy any securities, including the 4.75% Notes or the 8.25% Notes, nor shall it constitute a notice of redemption under the indenture governing the 4.75% Notes or the 2029 Notes Indenture, nor shall there be any offer, solicitation or sale of the 4.75% Notes, the 8.25% Notes or any other securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

Contact: Investors: Jeb Bachmann – Managing Director, Investor Relations – (615) 263-3024
Financial Media: David Gutierrez, Dresner Corporate Services – (312) 780-7204

Release – FreightCar America, Inc. Announces Milestone Multi-Year Order for 1,900 Railcars; Second Quarter Orders for Approximately 3,000 Railcars Represent a Commercial Inflection Point

Posted on by [email protected]
FreightCar America

Research News and Market Data on RAIL

07/06/2026

New Multi-Year Railcar Order Extends Backlog Visibility and Supports Second Quarter Commercial Momentum, Reflecting Customer Confidence in FreightCar America’s Commercial, Engineering and Manufacturing Platform

CHICAGO, July 06, 2026 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a leading North American manufacturer and supplier of freight railcars, railcar parts and components, today announced that it has entered into a new multi-year order for 1,900 railcars from a key customer, with deliveries scheduled through 2028. The Company also announced that second quarter orders totaled approximately 3,000 railcars, representing a commercial inflection point as demand for differentiated, agile manufacturing solutions continues to grow.

Highlights

  • Secured a new multi-year order for 1,900 railcars, with deliveries scheduled through 2028, expanding backlog visibility and reflecting customer confidence in the Company’s execution and manufacturing capabilities.
  • Second quarter orders totaled approximately 3,000 railcars, valued at approximately $300 million, with orders received across every core market segment, reflecting broad-based demand and product diversity.
  • Multiple first-time customer orders, together with meaningful repeat customer activity, underscore strength of commercial presence, product offering and manufacturing platform.

“Customers are increasingly choosing FreightCar America because we are delivering what the market needs in conditions where customers need us most. Anchored by our engineering capability, manufacturing agility and focus on quality, we continue to position ourselves to gain share and capture significant order momentum during the quarter,” commented Nick Randall, President and Chief Executive Officer of FreightCar America. “This new multi-year commitment for 1,900 railcars is a testament to that, marking a milestone for the Company and showcasing the confidence our customers put into our ability to execute over a sustained delivery horizon.”

Randall continued, “With approximately 3,000 railcars ordered in the quarter, we are seeing an inflection point in terms of commercial momentum across our differentiated product portfolio. These orders highlight the value customers place on our ability to move quickly, tailor solutions to their needs and support transportation capacity across the North American supply chain. We believe FreightCar America is well positioned as an execution-focused railcar manufacturer in a market where reliability, responsiveness and delivery performance matter more than ever.”

Certain orders referenced in this release are subject to customary documentation and completion of terms.

About FreightCar America

FreightCar America, headquartered in Chicago, Illinois, is a leading designer, producer and supplier of railroad freight cars, railcar parts and components. We also specialize in railcar repairs, complete railcar rebody services and railcar conversions that repurpose idled rail assets back into revenue service. Since 1901, our customers have trusted us to build quality railcars that are critical to economic growth and instrumental to the North American supply chain. To learn more about FreightCar America, visit www.freightcaramerica.com.

Forward-Looking Statements

This press release contains statements relating to our expected financial performance, financial condition, and/or future business prospects, events and/or plans that are “forward-looking statements” as defined under the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our estimates and assumptions only as of the date of this press release. Our actual results may differ materially from the results described in or anticipated by our forward-looking statements due to certain risks and uncertainties. These potential risks and uncertainties relate to, among other things, the cyclical nature of our business; adverse economic and market conditions, including inflation; material disruption in the movement of rail traffic for deliveries; fluctuating costs of raw materials, including steel and aluminum; delays in the delivery of raw materials; our ability to maintain relationships with our suppliers of railcar components; our reliance upon a small number of customers that represent a large percentage of our sales; the variable purchase patterns of our customers and the timing of completion, delivery and customer acceptance of orders; the highly competitive nature of our industry; potential unexpected changes in laws, rules, and regulatory requirements, including tariffs and trade barriers; and other competitive factors. We expressly disclaim any duty to provide updates to any forward-looking statements made in this press release, whether as a result of new information, future events or otherwise.

Investor Contact: [email protected]

Primary Logo

Source: FreightCar America, Inc.

View all news

Release – NN, Inc. Announces Major Breakthrough in its Medical Business

Posted on by [email protected]
Primary Logo

Research News and Market Data on NNBR

PDF Version

NN to manufacture critical components for a leading robotic-assisted surgery platform


CHARLOTTE, N.C., July 06, 2026 (GLOBE NEWSWIRE) — NN, Inc. (NASDAQ: NNBR) (“NN” or the “Company”), a global diversified industrial company that engineers, co-develops and manufactures precision components and assemblies with six sigma quality, today provided an update on developments in its Medical Products business, one of the Company’s key targeted growth markets. The components of the Medical Products growth program are:

  • Specialized quality control systems in the plants that make medical products
  • Dedicated, specialized CNC machining equipment
  • Dedicated special purpose floor space
  • Medical industry experts on staff
  • Attendance at top medical device shows
  • State-of-the-art stainless steel machined products
  • Global footprint in North America, China, South America, Europe

NN has achieved awards to support major OEMs in Ultrasound, Interventional Cardiology, Sports Medicine & Extremity Solutions, and Robotic-Assisted Surgery. Robotic-Assisted Surgery is a new breakthrough area of success and the focus of this press release. NN has now become qualified and has received initial POs tied to a leading robotic-assisted surgery platform. This momentum complements NN’s legacy medical work in surgical instruments, orthopedic tools/components, electrosurgical products, suture-related products, and precision medical components.

A recent and most difficult step to entering the Robot-Assisted Surgery market was passing a critical full-facility audit at NN’s Kentwood, Michigan plant. Successfully passing this audit was made possible by completing a multi-year investment program and installing a new quality system. With this new medical certification now steady-state, a large and well-known new customer has released its first purchase orders to NN, with immediate delivery and ramp-up requirements. This also provides NN with references and an avenue to quote and win additional programs.

With this new customer, the new medical certification, and new medical products, NN’s medical new business pipeline has increased in size by ~$25 million and is now approximately $75 million overall. This is now a meaningful component of NN’s total corporate new business pipeline of >$750 million which includes all products for all markets.

Robotic-assisted surgery is the fastest-growing method of surgical care, expanding at double-digit annual rates in the United States. The underlying growth of this key market reflects a strong secular growth opportunity for precision component suppliers like NN that possess the critical engineering capability, quality systems, and global manufacturing footprint to serve it. NN is uniquely positioned to participate in medical market growth as a qualified manufacturer. NN is actively investing into the medical market with dedicated staff, tradeshow attendance, additional equipment, and new products.

Harold Bevis, President and Chief Executive Officer of NN, Inc., commented, “This is a milestone event for NN’s medical products growth program and a direct payoff on the investments we have made over the last three years to establish a premier presence in this medical market. We needed to upgrade our quality system to the medical level and we have done it.

“Medical Products is one of our five targeted growth markets and we have been very deliberate about building the capabilities required to compete and win. This includes specialized machines, dedicated floor space, certified quality systems, and a dedicated medical team. Passing this full facility quality audit and securing our first newly associated purchase orders to make precision components for a leading robotic surgery platform is a good step forward for NN.”

Bevis continued, “Our precision stainless steel machining expertise supports these new markets well. We are successfully executing on our stated growth goals in the medical products market, and we intend to both grow with this particular customer, as well as more fully participate in the broader medical market.

“This medical products achievement is consistent with our growth program overall. We are partnering for long-term success with OEM category winners. We are successfully building the Company’s business profile in new markets and with new customers. Safety-critical, engineered components are our core value proposition. We support it with a clever team, material science, six sigma quality, and global manufacturing footprint. The medical products achievements announced today, combined with the strong momentum we are experiencing in data center and defense, continue to demonstrate that our entrepreneurial breakout growth program is working well.”

Bevis concluded, “NN is underway with a multi-year program of growing its business into new areas. It is awesome to have the Medical Products portion of the 5 Pillar growth program achieving breakthrough victories. The 5 pillars of break-out growth continue to be: data center and electric grid, defense and electronics, medical products, high-value vehicle products, and high-value stamped products.

We will combine this Medical Product new win information with our recent new wins in Data Center and adjust 2026 sales, adjusted EBITDA, and New Wins guidance, if needed, during NN’s next business and guidance update in August. We look forward to discussing this big advancement during that time.”

About NN, Inc.
NN, Inc., a global diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. Headquartered in Charlotte, North Carolina, NN has facilities in North America, South America, Europe, and China. For more information about the company and its products, please visit www.nninc.com.

Forward-Looking Statements
This press release contains express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the future growth of NN’s medical business, including NN’s expectations regarding current and future customers and programs, the size and future outlook of the medical market, including robotics-assisted surgery, NN’s competitive position in the medical market, expected new business wins for 2026, and NN’s 2026 performance and other statements that are not historical facts.

Forward-looking statements generally will be accompanied by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “guidance,” “intend,” “may,” “will,” “possible,” “potential,” “predict,” “project”, “achieve,” “growth,” “enable,” “improve,” or the negative of these terms, and similar words, phrases or expressions that convey uncertainty of future events or outcomes. Forward-looking statements involve a number of risks and uncertainties that are outside of management’s control and that may cause actual results to be materially different from such statements. Such factors include, among others, general economic conditions and economic conditions in the industrial sector; competitive influences; risks that current customers will commence or increase captive production; risks of capacity underutilization; quality issues; inflationary pressures and material changes in the costs and availability of raw materials, supply chain shortages and disruptions, the availability of labor and labor distributions along the supply chain; our dependence on certain major customers, some of whom are not parties to long-term agreements (and/or are terminable on short notice); the impact of acquisitions and divestitures, as well as expansion of end markets and product offerings; our ability to hire or retain key personnel; the restrictions contained in our debt agreements; the level of our indebtedness and our ability to financing at favorable rates, if at all, or to refinance existing debt as it matures; our ability to secure, maintain or enforce patents or other appropriate protections for our intellectual property; the impact on climate change on our operations; economic, social and geopolitical instability, military conflict, currency fluctuations, and other risks of doing business outside of the United States; and uncertainty of government policies and actions in respect to global trade and tariffs, including the potential impacts of tariffs on the United States economy, the economy of other countries in which we conduct operations and our industry, cyber liability or potential liability for breaches of our or our service providers’ information technology systems or business operations disruptions. The foregoing factors should not be construed as exhaustive and should be read in conjunction with the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s filings made with the U.S. Securities and Exchange Commission. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. New risks and uncertainties may emerge from time to time, and it is not possible for the Company to predict their occurrence or how they will affect the Company. The Company qualifies all forward-looking statements by these cautionary statements.

Investor & Media Contact: 
Joe Caminiti  
[email protected]
312-445-2870

Robotic Surgery Machine
 

NN Medical Surgery Image
Robotic Surgery Machine

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1db7369d-ec70-40e1-81f7-bf89fbbb3544

Primary Logo

Release – DLH Announces Leadership Transition

Posted on by [email protected]
logo

Research News and Market Data on DLHC

June 30, 2026

PDF Version

Zach Parker to Retire; Kathryn JohnBull Appointed CEO; Steve Oroho Appointed CFO

ATLANTA, June 30, 2026 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital transformation and cybersecurity, systems engineering and integration, and science research and development solutions to federal agencies, today announced the following leadership changes:

  • Zach Parker will retire from the role of Chief Executive Officer
  • The Board has appointed Kathryn JohnBull as CEO
  • The Board has appointed Steve Oroho as Chief Financial Officer

Zach Parker

Zach Parker will retire as DLH’s Chief Executive Officer and President effective at the close of business on June 30, 2026. To support a smooth leadership transition, Mr. Parker will remain with the Company as an advisor to the Board and incoming CEO through the end of the current fiscal year. He will continue to serve as a member of the Board and beginning in fiscal 2027 will serve as a consultant to the Company in support of certain strategic growth pursuits.

“Sixteen years ago, Zach Parker became the CEO of a $35 million revenue company that was insignificant to the Government Services industry,” said Chairman of the Board Rick Wasserman. “He built a team, and together, they built that organization into the DLH of today. His accomplishments have been exemplary in shaping the Company’s success and creating significant value for our shareholders and career opportunities for our employees. We are grateful for his leadership and pleased that the Company will continue to benefit from his deep industry knowledge, strategic perspective, and longstanding relationships through his continued service on the Board. We are also appreciative that the team he built is uniquely qualified and well positioned to lead us into the future. We wish Zach a long and enjoyable retirement and much happiness in the future.”

“I am proud of what our team has accomplished and excited about DLH’s future,” said Mr. Parker. “After 16 years as CEO, I believe this planned transition represents the right next step for the Company and for me personally. Kathryn has been a close partner, and I have great confidence in her ability to lead the Company through its next chapter. I look forward to supporting Kathryn, the leadership team, and the Board as we continue working to create sustainable long-term value for our shareholders.”

Kathryn JohnBull

Kathryn JohnBull has been appointed as DLH’s Chief Executive Officer and President upon Mr. Parker’s retirement. Ms. JohnBull brings deep public-company leadership experience, financial discipline, and a thorough understanding of the government services market to her new role. She joined DLH as Chief Financial Officer in 2012, and has been central to the Company’s growth, acquisition strategy, capital markets activities, financial operations, and investor engagement.

“Kathryn is exceptionally well prepared to lead DLH at this important moment in the Company’s evolution,” Mr. Wasserman continued. “During her 14 years with us, she has demonstrated a strong combination of leadership skills, financial acumen, operating discipline, customer understanding, and public-company experience. This promotion is well earned, and the Board is confident that Kathryn and her leadership team are well positioned to advance the Company’s strategy and compete for new business opportunities, which create value for our shareholders.”

“I am honored to lead DLH as we enter the next stage of our corporate journey,” said Ms. JohnBull. “Our company has been built by talented people, highly valued customer relationships, and an unwavering commitment to supporting critical government missions. As we look ahead, our focus will be clear: executing with discipline and excellence, delivering exceptional value for our customers, and investing in and empowering our employees. By embracing innovation and strengthening the capabilities that differentiate DLH, we will continue building a company where our employees will grow, our customers will be well served, and our business will thrive.”

Steve Oroho

Steve Oroho has been appointed as DLH’s Chief Financial Officer and Treasurer upon Ms. JohnBull’s appointment as CEO. Mr. Oroho joined DLH in 2018 and has served as Senior Vice President, Finance & Accounting. In that role, he has played an important part in the Company’s financial reporting, strategic planning, accounting, treasury, and business operations support. As Chief Financial Officer, Mr. Oroho will lead DLH’s finance organization, including accounting, financial planning and analysis, treasury, tax, investor relations, and related financial operations.

“Steve has been an important member of DLH’s finance leadership team and brings deep knowledge of the Company’s operations, financial systems, and strategic priorities,” said Ms. JohnBull. “His experience, judgment, and commitment to disciplined execution will serve DLH well as we continue to advance our strategic and financial objectives.”

“I am grateful for the opportunity to serve as DLH’s Chief Financial Officer,” said Mr. Oroho. “I look forward to continuing to work closely with Kathryn, the Board, and our leadership team to support our customers, strengthen our operating performance, and create sustainable value for our shareholders.”

About DLH:

DLH (NASDAQ: DLHC) enhances technology, public health, and cyber security readiness missions through science, technology, cyber, and engineering solutions and services. Our experts solve some of the most complex and critical missions faced by federal customers, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With a world-class workforce dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to innovative solutions to improve the lives of millions. For more information, visit www.DLHcorp.com. 

Contact Information:

Investor Relations
Chris Witty
(646) 438-9385
[email protected]

Media
[email protected]

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH`s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding the anticipated use of proceeds. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements due to a variety of factors, including: the failure to achieve the anticipated benefits of any future acquisition (including anticipated future financial operating performance and results); the inability to retain employees and customers; contract awards in connection with re-competes for present business and/or competition for new business; our ability to manage our debt obligations; compliance with bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid and award protests, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; significant delays or reductions in appropriations for our programs and broader changes in U.S. government funding and spending patterns; legislation that amends or changes discretionary spending levels or budget priorities; legal, regulatory, and political changes from the federal government that could result in economic uncertainty; the impact of inflation and higher interest rates; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2025, as well as interim quarterly filings thereafter. The forward-looking statements contained herein are not historical facts, but rather based on current expectations, estimates, assumptions and projections about our industry and business.

Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements.

Release – Conduent Announces Agreement to Sell Its Tolling Business to Quarterhill Inc. for $70 Million

Posted on by [email protected]

Research News and Market Data on CNDT

Conduent Bolsters Financial Position Tolling Agreement Follows Recently Announced Agreement to Sell Its Public Transit Business

June 30, 2026

Corporate Transportation

Conduent Will Also Receive a 7% Interest in Quarterhill Inc.

Conduent Bolsters Financial Position

Tolling Agreement Follows Recently Announced Agreement to Sell Its Public Transit Business

FLORHAM PARK, N.J., June 30, 2026 — Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services provider, today announced that it has entered into a definitive agreement to sell its Tolling business (a division of Conduent Transportation) to Quarterhill Inc. (TSX: QTRH) (OTCQX: QTRHF), a leading global provider of intelligent transportation system solutions.

The sale has a purchase price of $70 million in cash, and Quarterhill will assume most liabilities associated with the business, including all surety bond obligations, further improving Conduent’s financial profile. The structure of the transaction enhances Conduent’s financial flexibility and reduces exposure to non-core obligations.

The transaction is expected to close before the end of 2026.

This agreement follows a separate transaction, announced in May, to sell the Public Transit business, also part of Conduent’s Transportation division, which is similarly expected to close before the end of 2026.

Together, these transactions simplify Conduent’s portfolio and increase focus on its core businesses, enhancing the predictability and durability of Conduent’s earnings profile.

“This Tolling transaction, alongside the previously announced Public Transit agreement, advances our strategy to simplify our portfolio, sharpen focus on our core businesses, and strengthen our financial foundation,” said Harsha V. Agadi, Conduent President and Chief Executive Officer. “We are continuing our strategic journey to enhance long-term value creation, including simplifying our business, strengthening the balance sheet, and increasing sustainable free cash flow.

“With more than four decades of experience in tolling, Quarterhill is extremely well positioned to support the Conduent Tolling team and its clients. As we move toward closing, we remain committed to delivering outstanding quality and performance for all Transportation clients while ensuring smooth transitions for both clients and associates.”

As part of the transaction, Conduent will also receive a 7% interest in Quarterhill Inc. along with registration rights and board observer rights, providing potential upside participation in future value creation.

With operations in the United States and United Kingdom, Conduent’s Tolling business provides mission‑critical technology that enables all‑electronic tolling, roadside and back‑office processing, image review, violation enforcement, and analytics. It supports more than 14 million tolling transactions per day.

Additional details of the transaction are outlined in Conduent’s 8-K filed with the U.S. Securities and Exchange Commission (SEC) today.

About Conduent
Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 48,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $80 billion in government payments annually, enabling approximately 2.0 billion customer service interactions annually, empowering millions of employees through HR services every year and processing over 14 million tolling transactions every day. Learn more at www.conduent.com.

About Quarterhill
Quarterhill is a global leader in the Intelligent Transportation System (ITS) industry, advancing mobility through smart infrastructure solutions that reduce congestion, improve roadway safety, and create more sustainable travel. Each year, Quarterhill’s platforms process billions of transactions, perform compliance and safety inspections on millions of commercial vehicles, and enable transportation agencies worldwide to optimize thousands of lanes of traffic to improve travel for everyone. Leveraging advanced artificial intelligence and machine learning technologies, Quarterhill’s platform delivers automation and predictive insight to help agencies manage transportation networks more efficiently. By working in close partnership with governments, communities, and industry leaders, Quarterhill is building today’s connected roadways while shaping the next generation of intelligent, resilient mobility. Quarterhill is listed on the TSX under the symbol QTRH and on the OTCQX Best Market under the symbol QTRHF. Learn more at www.quarterhill.com.

###

Media Contacts

Remy Kaul

Conduent

[email protected]

Lands’ End Announces CEO Transition, Positioning Company for Next Phase of Growth

Posted on by [email protected]
Lands' End

Research News and Market Data on LE

Jun 30, 2026

Consumer Brand and Digital Transformation Executive Charlie Cole Named Chief Executive Officer

Andrew McLean to Transition to Advisory Role to Support Smooth Transition

DODGEVILLE, Wis., June 30, 2026 (GLOBE NEWSWIRE) — Lands’ End, Inc. (NASDAQ: LE) today announced that its Board of Directors has appointed consumer brand and digital transformation executive Charlie Cole as Chief Executive Officer and a member of the Board of Directors, effective July 13, 2026. Mr. Cole will succeed Andrew McLean, who will step down as CEO and a member of the Board of Directors.

Mr. Cole’s appointment builds on the strong execution of the Company’s solutions-based strategy under Mr. McLean that strengthened the Lands’ End brand, improved operating performance, repositioned the Company for long-term growth, and culminated in the Company’s strategic joint venture with WHP Global.

“Our responsibility as a Board is to ensure Lands’ End has the right leader for every stage of its evolution,” said Josephine Linden, Chair of the Board of Directors. “Charlie has spent his career transforming iconic consumer brands by combining disciplined operating execution with technology-enabled innovation, and the Board is confident that his expertise will enable him to execute and expand on the strategy the Company recently laid out while positioning Lands’ End exceptionally well to drive the next phase of profitable growth and sustainable shareholder value creation.”

Mr. Cole said, “Lands’ End is one of America’s most iconic brands, built on quality, service, and enduring customer relationships. Andrew and the entire team have created a strong platform for the future, and I am honored to build upon that foundation, leveraging my technology and AI experience to create an even more personalized, engaging and productive customer experience. I look forward to working alongside Lands’ End’s talented employees, partners, customers and shareholders as we write the next chapter of the Lands’ End story.”

Mrs. Linden added: “On behalf of the Board, I want to thank Andrew for his outstanding leadership. During his tenure, Lands’ End executed a strategic transformation that strengthened both the business and the balance sheet and created meaningful opportunities for future value creation. Andrew’s leadership in establishing the WHP Global joint venture represents a significant milestone in unlocking the long-term potential of the Lands’ End brand. We are grateful that he will continue supporting the Company during this transition.”

“The continued return of capital to shareholders through the Company’s $100 million share repurchase program authorized in April is demonstration of the Board’s confidence in the future and value of this great Company,” concluded Mrs. Linden.

Mr. McLean said: “It has been a privilege to lead Lands’ End and work alongside such an exceptional team. Together we strengthened the brand, improved our operating performance, expanded strategic opportunities, and positioned the Company for its next phase of growth. I have tremendous confidence in Charlie’s leadership and believe Lands’ End is well positioned to continue creating value for customers, employees and shareholders. I remain committed to ensuring a smooth transition.”

The Board retained leading executive search firm Heidrick & Struggles to assist in its search.

Charlie Cole Biography

Charlie Cole is a consumer brand executive with more than two decades of leadership experience spanning digital commerce, technology, artificial intelligence and omnichannel retail. Most recently, he served as Interim Chief Digital Officer of Thuma. Previously, he was President of XGen AI, an AI-powered commerce software company acquired by Zoovu in 2026, Chief Executive Officer of Tribute Technology, Chief Executive Officer of FTD, Chief Digital Officer of TUMI, and Global Chief eCommerce Officer of Samsonite. Throughout his career, Mr. Cole has helped iconic consumer brands accelerate growth through customer-centric innovation, digital transformation and operational excellence. He holds a Bachelor of Arts in Business Administration from the University of Washington.

About Lands’ End, Inc.

Lands’ End, Inc. (NASDAQ:LE) is a leading digital retailer of solution-based apparel, swimwear, outerwear, accessories, footwear, home products and uniforms. Lands’ End offers products online at www.landsend.com, through third-party distribution channels and our own Company Operated stores. Lands’ End also offers products to businesses and schools, for their employees and students, through the Outfitters distribution channel. Lands’ End is a classic American lifestyle brand that creates solutions for life’s every journey.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding positioning the Company for growth and value; the expected timing and effect of the CEO transition and the appointment of Mr. Cole; the Board ensuring future leadership; confidence in executing and expanding strategy, building on the Company’s platform, improved customer experience and the Company’s next chapter; the long-term potential of the Lands’ End brand;  the share repurchase program and its anticipated scale and impact; and the future value of the Company. Forward-looking statements are based on beliefs and assumptions and are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if the underlying beliefs and assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. These risks and uncertainties include those risks, uncertainties and factors discussed in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended January 30, 2026 and “Part II, Item 1A Risk Factors” of the Quarterly Report on Form 10-Q for the quarter ended May 1, 2026. Forward-looking statements speak only as of the date on which they are made. The Company expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable securities laws and regulations.

CONTACTS:

Investors:
Lands’ End, Inc.
Bernard McCracken
Chief Financial Officer
(608) 935-4100

ICR, Inc.
Tom Filandro
(646) 277-1235
[email protected]

Media:
FGS Global
Andy Duberstein/Hayley Cook
[email protected]

Release – Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

Posted on by [email protected]
Unicycive Therapeutics, Inc

Research News and Market Data on UNCY

June 30, 2026 7:05am EDT Download as PDF

— Complete Response Letter relates to deficiencies previously identified at third-party manufacturing vendor —

— FDA inspection of third-party facility did not occur during the NDA resubmission review —

— Labeling discussions currently underway; latest communication received by the Company from FDA on June 29 regarding carton and container label —

— FDA did not raise concerns regarding the clinical efficacy or safety data of OLC, and no additional data was requested —

MOUNTAIN VIEW, Calif., June 30, 2026 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the resubmitted New Drug Application (NDA) for oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The FDA has not raised any concerns regarding clinical efficacy or safety data, and no additional data was requested from Unicycive.

The CRL is based on the same third-party manufacturing deficiencies that were identified in the previous CRL issued in June 2025. Unicycive understands that the FDA has not yet conducted its inspection of that third-party manufacturing vendor as part of the review process of the resubmitted NDA. The NDA for OLC had been resubmitted based on Unicycive’s belief of continued progress by the original third-party manufacturing vendor in resolving FDA-cited deficiencies and demonstrating inspection readiness. Unicycive previously discussed these milestones during a Type A meeting with the FDA in September 2025, which was held to obtain feedback and alignment on resolving the deficiencies identified in the Company’s CRL related to the compliance status of the vendor. The FDA did not express any concerns about the third-party manufacturer’s progress and no additional issues were raised by the FDA at the Type A meeting.

“We remain confident in the efficacy and safety of OLC,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “We are in active and ongoing discussion with the FDA regarding label and packaging, and we are optimistic that there will be a successful inspection of the third-party manufacturing vendor and that we will be able to expeditiously resubmit the NDA.”

The OLC NDA is supported by data from three clinical studies: a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in chronic kidney disease (CKD) patients on dialysis, multiple preclinical studies, as well as chemistry, manufacturing and controls (CMC) data.

About Oxylanthanum Carbonate
OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden.
Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035.

About Hyperphosphatemia
Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.1 Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.

1Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145.

About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Forward-looking statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; our need to raise substantial additional capital in the future to fund our continuing operations and the development and commercialization of our current product candidates and future product candidates; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; risks related to delays in obtaining or failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; and our failure, or the failure of our third-party manufacturers, or their subcontractors, to comply with cGMPs or other applicable regulations, which could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our product candidates and harm our business and results of operations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:
Kevin Gardner
LifeSci Advisors
[email protected]

Media Contact:
Layne Cosgrove
Real Chemistry
[email protected]

Primary Logo

Source: Unicycive Therapeutics, Inc.

Released June 30, 2026

Release – NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

Posted on by [email protected]

Research News and Market Data on NRSN

  • First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS
  • TDP-43 pathology is present in more than 97% of ALS cases and is widely recognized as a central driver of disease progression
  • PrimeC demonstrates target engagement with consistent effects across clinical outcomes, survival, and biomarkers, supporting its potential as a disease-modifying therapy

CAMBRIDGE, Mass., June 29, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that its Phase 2b PARADIGM study of PrimeC in amyotrophic lateral sclerosis (ALS) has successfully met its primary efficacy endpoint, demonstrating a statistically significant reduction in TDP-43 levels compared to placebo. This is the first randomized, double-blind, placebo-controlled clinical study to demonstrate a treatment-associated reduction in TDP-43 in people living with ALS. The analysis was performed using the NeuroDex ExoSORT procedure, an immunoaffinity-based methodology that selectively isolates neuron-derived extracellular vesicles (NDEs). This approach enables measurement of neuron-derived TDP-43, providing a CNS-relevant signal that can be distinguished from TDP-43 released by non-neuronal cells and peripheral tissues.

TDP-43 is the defining pathological hallmark of ALS, present in more than 97% of cases, and is widely recognized as a central driver of disease progression. The observed reduction in TDP-43 provides biological evidence that PrimeC is engaging a core disease mechanism.

Primary Efficacy Endpoint Achieved with Statistical Significance

The randomized, double-blind, placebo-controlled Phase 2b PARADIGM study evaluated the safety, tolerability, biomarkers and efficacy of PrimeC in people with ALS. At Day 180, the pre-specified primary endpoint timepoint, PrimeC produced a statistically significant reduction in TDP-43 versus placebo (p=0.0421). The effect was sustained and deepened over the full 18 months of the study, with continuously treated PrimeC participants maintaining lower TDP-43 levels than the placebo arm at Day 540 (p<0.001).

These findings build upon previously reported clinical outcomes from the PARADIGM study, including:

  • Statistically significant slowing of ALSFRS-R decline at 12 and 18 months (36.5%, p=0.008; 32.8%, p=0.007)
  • Statistically significant ~15-month median survival benefit (HR 0.35, p=0.004)
  • Consistent modulation of TDP-43, iron-regulatory and ALS-associated microRNA, supporting multi-target engagement
  • Favorable safety and tolerability profile with no new safety signals observed over up to 18 months of treatment

“Achieving the primary endpoint of PARADIGM with a statistically significant reduction in TDP-43 marks a defining moment for NeuroSense and for ALS research,” said Alon Ben-Noon, Chief Executive Officer of NeuroSense. “For decades, TDP-43 has been recognized as the pathological signature of ALS, yet demonstrating a treatment-associated reduction in people with ALS has remained elusive. Combined with the clinically meaningful slowing of disease progression, significant survival benefit, and consistent biomarker findings previously reported from PARADIGM, these results provide a compelling and highly differentiated body of evidence supporting PrimeC’s potential as a disease-modifying therapy. We believe this growing dataset further validates our scientific approach and positions PrimeC as one of the most comprehensively supported therapeutic candidates in ALS today.”

“One of the central questions in ALS drug development is whether a therapy is truly affecting the underlying biology of the disease,” said Prof. Merit Cudkowicz, MD, MSc, Director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, and Professor of Neurology at Harvard Medical School. “The TDP-43 findings reported in PARADIGM are particularly important because they suggest target engagement of a pathological process present in the majority of people with ALS. When viewed together with the previously reported safety, biomarker and clinical outcome data, and the high unmet need, these results provide compelling data supporting advancement into a confirmatory Phase 3 clinical trial.”

“It is remarkable to see that the increase in NDE-associated TDP-43 observed in the placebo group follows the same trajectory as that identified in our longitudinal studies. This effect, together with the positive outcome of PARADIGM, highlights the promise of TDP-43 as a biomarker for monitoring treatment response,” said Dr. Erez Eitan, CEO of NeuroDex.

Having secured FDA clearance to initiate its global Phase 3 (PARAGON) study, NeuroSense is advancing trial preparations while progressing regulatory interactions across multiple jurisdictions, including Canada.

About NeuroSense

NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The Company’s lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.

NeuroSense has generated compelling clinical data from its Phase 2b PARADIGM study in ALS, demonstrating meaningful slowing of disease progression. The Company also reported significant biological activity across multiple biomarkers associated with ALS, including microRNAs, supporting PrimeC’s multi-target mechanism of action. Notably, long-term follow-up data indicated a meaningful survival benefit, representing a potentially important advancement in the treatment of ALS.

NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pivotal Phase 3 clinical trial (PARAGON) in ALS, which is expected to enroll approximately 300 participants, primarily in the United States.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation to potentially inhibit the progression of ALS and AD.

About ALS

Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

About ExoSORT and Neuron-derived EV

ExoSORT™ is NeuroDex’s proprietary automated platform for the enrichment of neuron-derived extracellular vesicles (NDEs) from blood samples. Utilizing a combination of highly specific neuronal antibodies and a scalable 96-well workflow, ExoSORT™ selectively isolates extracellular vesicles originating from the brain, increasing the neuronal signal by more than 50-fold compared to conventional plasma analyses.

By enriching for brain-derived vesicles, ExoSORT™ enables detection of disease-associated proteins present in multiple tissues, like TDP-43.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the potential of PrimeC. Further, certain forward-looking statements, including statements regarding future development of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding outcomes and the timing of current and future clinical trials; the risk that PrimeC will not advance towards later-stage development, timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

SOURCE NeuroSense

For further information: For further information: Email: [email protected] | Tel: +972 (0)9 799 6183

Release – Star Equity Holdings Added to the Russell Microcap® Index

Posted on by [email protected]
Primary Logo

Research News and Market Data on STRR

Jun 29, 2026

Download PDF

OLD GREENWICH, Conn., June 29, 2026 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR and STRRP) (“Star” or the “Company”), a diversified holding company, announced today the Company’s common stock has been added to the Russell Microcap® Index following the 2026 Russell indexes reconstitution, which became effective after US market close on June 26, 2026.

The reconstitution of the Russell U.S. Indexes captures the 4,000 largest U.S. stocks as of April 30, 2026, ranked by total market capitalization. The Russell Microcap® Index measures the performance of the microcap segment of the U.S. equity market and is used by institutional investors and investment managers as a benchmark for microcap equities.

Jeff Eberwein, CEO of Star, commented, “We are pleased to join the Russell Microcap® Index, a meaningful milestone that reflects our progress in building a diversified platform for long-term shareholder value creation. Inclusion in this benchmark expands our visibility within the institutional investment community and introduces our stock to additional microcap investors seeking fundamentally driven, value-oriented opportunities. We believe this recognition will further broaden awareness as we continue executing on our strategy.”

About Star Equity Holdings, Inc. 
Star Equity Holdings, Inc. is a diversified holding company that seeks to build long-term shareholder value by acquiring, managing, and growing businesses with strong fundamentals and market opportunities. Its current structure comprises four segments: Building Solutions, Business Services, Energy Services, and Investments. For more information visit www.starequity.com.

Building Solutions
The Building Solutions division operates in three specialties: (i) modular building manufacturing; (ii) structural wall panel and wood foundation manufacturing, including building supply distribution operations; and (iii) glue-laminated timber (glulam) column, beam, and truss manufacturing.

Business Services
The Business Services division provides flexible and scalable recruitment solutions to a global clientele, servicing organizations at all levels, from entry-level positions to the C-suite. The division focuses on mid-market and enterprise organizations worldwide, partnering consultatively with talent acquisition, HR, and procurement leaders to build diverse, high-impact teams and drive business success.

Energy Services
The Energy Services division engages in the rental, sale, and repair of downhole tools used in the oil and gas, geothermal, mining, and water-well industries.

Investments
The Investments division manages and finances the Company’s real estate assets as well as its investment positions in private and public companies.

About FTSE Russell, an LSEG Business
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. 

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $21.20 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by LSEG. 

For more information, visit FTSE Russell.

For more information contact:
The Equity Group
Lena Cati
Senior Vice President
212-836-9611
[email protected]

Release – Alliance Authentic Expands Its Preservation Platform Across Collecting, From Vinyl to Funko to Handmade by Robots

Posted on by [email protected]
Primary Logo

Research News and Market Data in AENT

Forbes called Alliance Authentic “a one-of-a-kind platform” for “a new generation of record buyers”

Newly preserved vinyl from Olivia Rodrigo, Harry Styles, Zara Larsson, Charli xcx, Karol G, Hayley Williams, and Angine de Poitrine

Launching newly preserved figures from Funko and Handmade by Robots

PLANTATION, Fla., June 29, 2026 (GLOBE NEWSWIRE) — Alliance Authentic, part of Alliance Entertainment (Nasdaq: AENT), the largest distributor of physical media in the U.S., today expanded its preservation platform beyond vinyl for the first time, launching preserved Funko and Handmade by Robots collectibles. Alliance Authentic is the only platform that preserves the records and collectibles fans care about most and carries each one’s verified identity to every owner who comes next. The company is creating a new category: permanently preserved collectibles. The expansion arrives on a rebuilt Alliance Authentic platform, redesigned around how collectors discover, preserve, and pass on what they own.

Every preserved Alliance Authentic release meets five standards: curated, numbered, limited, certified uncirculated, and NFC-secured. Each collectible is encapsulated in its original, uncirculated condition, individually numbered, and given an NFC-secured identity that travels to whoever owns it next. For vinyl, each preserved run is fixed and final, never added to. When a preserved collectible changes hands, its verified identity, condition, and full history travel with it. Every owner inherits the proof, not just the object. See how preservation works: https://www.allianceauthentic.com/how-preservation-works

“Every collector has a record that means everything to them,” said Jeffrey Smith, SVP of Sales and Marketing at Alliance Authentic. “And it’s not a generational thing, across ages, across collectors, that feeling is the same. We built a preservation system for exactly that, to keep a record in the moment it’s verified, certified, uncirculated, and treat it as the work of art it already is. There’s nothing cooler than an encapsulated Japanese import of Star Wars: A New Hope with the obi strip. And a Handmade by Robots figure or a Funko is just as cool to a different kind of collector. Opening this preservation system up to all of it, that’s what I’m excited about. A fan is a fan of what they love, and we’re here to protect it.”

Visit the new Alliance Authentic and browse the preserved vinyl catalog, home of The Ultimate Vinyl Collectible™: https://allianceauthentic.com

Explore the preserved Handmade by Robots figures, The Ultimate Fan Collectible: https://allianceauthentic.com/shop/search?_pg=hmbr

Explore the preserved Funko collectibles, The Ultimate Fan Collectible: https://allianceauthentic.com/shop/search?_pg=funko

About Alliance Authentic

Alliance Authentic is the only platform that preserves the records and collectibles fans care about most and carries each one’s verified identity to every owner who comes next. Part of Alliance Entertainment (Nasdaq: AENT), the largest distributor of physical media in the U.S. Learn more at allianceauthentic.com.

About Alliance Entertainment

Alliance Entertainment (NASDAQ: AENT) is a premier distributor and fulfillment partner for the entertainment and pop culture collectibles industry. With more than 340,000 unique in-stock SKUs – including over 57,300 exclusive titles across compact discs, vinyl LPs, DVDs, Blu-rays, and video games – Alliance offers the largest selection of physical media in the market. Our vast catalog also includes licensed merchandise, toys, retro gaming products, and collectibles, serving over 35,000 retail locations and powering e-commerce fulfillment for leading retailers. Alliance also owns and operates proprietary collectibles brands, including Handmade by Robots™, a stylized vinyl figure line featuring licensed characters from leading entertainment franchises, and Alliance Authentic™, a premium platform for authentic, certified, and individually numbered entertainment collectibles. In addition, Alliance operates Endstate Authentic, a dedicated NFC-enabled authentication and digital product identity platform supporting authenticated collectibles, resale, and brand protection. Leveraging decades of operational expertise, exclusive sourcing relationships, and a capital-light, scalable infrastructure, Alliance connects fans and collectors to the products, franchises, and experiences they value across formats and generations.

Forward Looking Statements

Certain statements included in this Press Release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics and projections of market opportunity. These statements are based on various assumptions, whether identified in this Press Release, and on the current expectations of Alliance’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by an investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Alliance. These forward-looking statements are subject to a number of risks and uncertainties, including risks relating to the anticipated growth rates and market opportunities; changes in applicable laws or regulations; the ability of Alliance to execute its business model, including market acceptance of its systems and related services; Alliance’s reliance on a concentration of suppliers for its products and services; increases in Alliance’s costs, disruption of supply, or shortage of products and materials; Alliance’s dependence on a concentration of customers, and failure to add new customers or expand sales to Alliance’s existing customers; increased Alliance inventory and risk of obsolescence; Alliance’s significant amount of indebtedness; our ability to refinance our existing indebtedness; our ability to continue as a going concern absent access to sources of liquidity; risks that a breach of the revolving credit facility could result in the lender declaring a default and that the full outstanding amount under the revolving credit facility could be immediately due in full, which would have severe adverse consequences for the Company; known or future litigation and regulatory enforcement risks, including the diversion of time and attention and the additional costs and demands on Alliance’s resources; Alliance’s business being adversely affected by increased inflation, uncertainty regarding tariffs, higher interest rates and other adverse economic, business, and/or competitive factors; geopolitical risk and changes in applicable laws or regulations; as well as our financial condition and results of operations; substantial regulations, which are evolving, and unfavorable changes or failure by Alliance to comply with these regulations; product liability claims, which could harm Alliance’s financial condition and liquidity if Alliance is not able to successfully defend or insure against such claims; availability of additional capital to support business growth; and the inability of Alliance to develop and maintain effective internal controls.

For press inquiries, please contact:

Max Lefkowitz – [email protected]
Anna DeNelsky – [email protected]
Matt Hanks – [email protected]

For investor inquiries, please contact:

Dave Gentry
RedChip Companies, Inc.
1-800-REDCHIP (733-2447)
1-407-644-4256
[email protected]